ONO Pharmaceutical Co (OPHLF) Price & Analysis
OPHLF Stock Chart & Stats
- Day’s Range
- $14.10 - $14.10
- 52-Week Range
- $11.08 - $18.67
- Previous Close
- $14.10
- Volume
- 99
- Average Volume (3M)
- 750
- Market Cap
- $6.72B
- Enterprise Value
- $960.85B
- Total Cash (Recent Filing)
- $258.26B
- Total Debt (Recent Filing)
- $109.99B
- Price to Earnings (P/E)
- 14.2
- Beta
- 0.57
- Next Earnings
- Feb 01, 2027
- EPS Estimate
- 0.3
- Next Dividend Ex-Date
- Mar 30, 2027
- Dividend Yield
- 3.59%
Bulls Say, Bears Say
Bulls Say
Strong Profitability
Sustained gross and operating margins at these levels indicate meaningful pricing power and cost control in ONO’s prescription-drug business. That profitability provides an enduring earnings cushion and supports continued investment in research, development, commercialization, and partnerships.
Conservative Balance Sheet
Very low leverage and a substantial equity base give ONO financial resilience through product cycles and earnings normalization. The conservative balance sheet preserves capacity to fund development, commercial activities, and shareholder returns without relying heavily on additional borrowing.
Robust Cash Generation
Strong operating and free cash flow, closely tracking reported earnings, supports the quality and convertibility of ONO’s profits. This recurring internal funding can help sustain research investment, licensing activity, and capital returns while reducing dependence on external financing.
Bears Say
Recent Revenue Decline
The recent contraction in revenue signals softer momentum in the marketed-product portfolio and reduces visibility on near-term expansion. If this trend persists, it could limit operating leverage and make continued earnings growth more dependent on successful launches or partnerships.
Margin Normalization
Material net-margin compression shows that ONO’s unusually strong earlier profitability has not been fully sustained. Continued normalization could constrain earnings growth even if revenue stabilizes, leaving less surplus to reinvest in the pipeline or distribute to shareholders.
Debt Has Increased
The increase from previously minimal debt introduces a less conservative element to ONO’s financial profile. Although current leverage remains low, additional borrowing can gradually reduce flexibility and increase the importance of maintaining strong cash generation as profitability normalizes.
ONO Pharmaceutical Co News
ONO Pharmaceutical’s Alzheimer’s Trial Milestone: What ONO‑2020 Could Mean for OPHLF Investors
ONO Pharmaceutical Co ($OPHLF) announced an update on their ongoing clinical study. Ono Pharmaceutical Co., Ltd. (OPHLF) has completed a mid‑stage trial called “A Phase II, 26‑week, Double‑blind, Placebo‑controlled Study
ONO-6414: New First-in-Human Ulcerative Colitis Study Puts ONO Pharmaceutical on Investors’ Radar
ONO Pharmaceutical Co ($OPHLF) announced an update on their ongoing clinical study. ONO Pharmaceutical Co., Ltd. (OPHLF) has filed a new Phase 1 trial titled “A Phase 1, Randomized, Double-Blind,
OPHLF FAQ
What was ONO Pharmaceutical Co’s price range in the past 12 months?
What is ONO Pharmaceutical Co’s market cap?
When is ONO Pharmaceutical Co’s upcoming earnings report date?
How were ONO Pharmaceutical Co’s earnings last quarter?
Is ONO Pharmaceutical Co overvalued?
Does ONO Pharmaceutical Co pay dividends?
What is ONO Pharmaceutical Co’s EPS estimate?
How many shares outstanding does ONO Pharmaceutical Co have?
What happened to ONO Pharmaceutical Co’s price movement after its last earnings report?
Which hedge fund is a major shareholder of ONO Pharmaceutical Co?
What is the TipRanks Smart Score and how is it calculated?
Company Description
ONO Pharmaceutical Co
Ono Pharmaceutical Co., Ltd., along with its affiliated companies, is engaged in the global development, manufacturing, procurement, and sale of a diverse range of pharmaceutical products and diagnostic tools. Its diverse oncology portfolio includes OPDIVO intravenous infusions, KYPROLIS for injection, MEKTOVI, VELEXBRU, and ADLUMIZ tablets, along with BRAFTOVI capsules, all prescribed for various malignant tumors. It also provides EMEND capsules and PROEMEND intravenous injections to alleviate chemotherapy-induced nausea and vomiting, and DEMSER capsules for managing symptoms in pheochromocytoma patients. Beyond oncology, the company's offerings span multiple therapeutic areas. For metabolic disorders, it supplies GLACTIV and FORXIGA tablets for type 2 diabetes. Cardiovascular health is supported by ONOACT injections for tachyarrhythmia, CORALAN for chronic heart failure, and OPALMON tablets addressing peripheral circulatory disorders. Autoimmune conditions like rheumatoid arthritis are treated with ORENCIA injections. Neurological therapies include RIVASTACH patches for Alzheimer's disease and ONGENTYS tablets for Parkinson's disease. Other notable products are PARSABIV intravenous injections for dialysis patients, STAYBLA tablets for overactive bladder, ONON capsules and dry syrups for bronchial asthma and allergic rhinitis, and RECALBON tablets for osteoporosis, with JOYCLU intra-articular injection available to improve joint function. Moreover, the company is heavily invested in research and development, with a pipeline targeting a wide array of diseases. This includes various malignancies such as esophageal, urothelial, Hodgkin's lymphoma, ovarian, bladder, prostate, hepatocellular, pancreatic, biliary tract, gastric, thyroid, colorectal, melanoma, acute myeloid leukemia, non-small cell lung cancer, and virus-positive/negative solid tumors, as well as primary central nervous system lymphoma. Beyond cancer, its developmental efforts extend to myelodysplastic syndrome, polymyositis/dermatomyositis, tachyarrhythmia, pemphigus, generalized scleroderma, enthesopathy, diabetic polyneuropathy, neurodegenerative and autoimmune disorders, narcolepsy, and thrombosis. Established in 1717, the company maintains its corporate headquarters in Osaka, Japan.
- Sector
- Healthcare
- Industry
- Drug Manufacturers - General
- CEO
- Gyo Sagara
- Employees
- 4,206
- Website
- www.ono-pharma.com
- Address
- 8-2, Kyutaromachi 1-chome, Osaka, OS, 541-8564, JP
ONO Pharmaceutical Co (OPHLF) Earnings & Revenues
OPHLF Earnings Call
Earnings Call SentimentNeutral
Mixed but balanced. The quarter delivered the company's highest-ever Q1 revenue (up 8.4% YoY) driven by strong FORXIGA performance and the addition of Deciphera (notably QINLOCK and ROMVIMZA). Strategic pipeline moves (povetacicept acquisition) and regulatory approvals/positive opinions support medium-term growth. However, near-term profitability was weakened by Deciphera operating losses, acquisition-related amortization and increased R&D/SG&A, while OPDIVO faces competitive pressure and slower recovery in lung cancer prescriptions. Management maintained full-year guidance, signaling confidence but with clear execution and timing risks.
View all OPHLF earnings summariesOPHLF Stock 12 Month Forecast
Average Price Target
Technical Analysis
Overall Consensus
| Indicator | Bullish | Neutral | Bearish |
|---|---|---|---|
| Overall Consensus | 3 | 5 | 14 |
| Technical Analysis | 3 | 5 | 2 |
| Moving Averages | 0 | 0 | 12 |